These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18305426)

  • 1. Novel prodrugs for targeting diagnostic and therapeutic radionuclides to solid tumors.
    Kassis AI; Korideck H; Wang K; Pospisil P; Adelstein SJ
    Molecules; 2008 Feb; 13(2):391-404. PubMed ID: 18305426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
    Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
    Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors.
    Pospisil P; Wang K; Al Aowad AF; Iyer LK; Adelstein SJ; Kassis AI
    Cancer Res; 2007 Mar; 67(5):2197-205. PubMed ID: 17332350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chemical, physical, and biologic properties of tumor-targeting radioiodinated quinazolinone derivative.
    Wang K; Kirichian AM; Aowad AF; Adelstein SJ; Kassis AI
    Bioconjug Chem; 2007; 18(3):754-64. PubMed ID: 17385903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrugs: effective solutions for solubility, permeability and targeting challenges.
    Hu L
    IDrugs; 2004 Aug; 7(8):736-42. PubMed ID: 15334306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymersome nanoreactors with tumor pH-triggered selective membrane permeability for prodrug delivery, activation, and combined oxidation-chemotherapy.
    Mukerabigwi JF; Yin W; Zha Z; Ke W; Wang Y; Chen W; Japir AAMM; Wang Y; Ge Z
    J Control Release; 2019 Jun; 303():209-222. PubMed ID: 31026547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-targeted liposomes in cancer therapy and imaging.
    Sofou S; Sgouros G
    Expert Opin Drug Deliv; 2008 Feb; 5(2):189-204. PubMed ID: 18248318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
    Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
    J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radionuclide cancer therapy.
    Hoefnagel CA
    Ann Nucl Med; 1998 Apr; 12(2):61-70. PubMed ID: 9637275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.
    Prabhu S; Boswell CA; Leipold D; Khawli LA; Li D; Lu D; Theil FP; Joshi A; Lum BL
    Ther Deliv; 2011 Jun; 2(6):769-91. PubMed ID: 22822508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino acids as promoieties in prodrug design and development.
    Vig BS; Huttunen KM; Laine K; Rautio J
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1370-85. PubMed ID: 23099277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
    Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
    Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.
    Dahan A; Khamis M; Agbaria R; Karaman R
    Expert Opin Drug Deliv; 2012 Aug; 9(8):1001-13. PubMed ID: 22703376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor.
    Nkepang G; Bio M; Rajaputra P; Awuah SG; You Y
    Bioconjug Chem; 2014 Dec; 25(12):2175-88. PubMed ID: 25351441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in drug delivery to the central nervous system by the prodrug approach.
    Pavan B; Dalpiaz A; Ciliberti N; Biondi C; Manfredini S; Vertuani S
    Molecules; 2008 May; 13(5):1035-65. PubMed ID: 18560328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prodrugs as drug delivery system in oncology.
    Delahousse J; Skarbek C; Paci A
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):937-958. PubMed ID: 31392391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of dendrimer prodrugs.
    Kojima C
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1303-15. PubMed ID: 26028253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
    Liang D; Miller GH; Tranmer GK
    Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect.
    Guo H; Sun S; Yang Z; Tang X; Wang Y
    J Control Release; 2015 Jul; 209():27-36. PubMed ID: 25883028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prodrugs in cardiovascular therapy.
    Sandros MG; Sarraf CB; Tabrizian M
    Molecules; 2008 May; 13(5):1156-78. PubMed ID: 18560335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.